Книги: "Hepatitis A Vaccination"

1

Damme, Pierre van. Hepatitis B: Epidemiology and evaluation of vaccination. Antwerpen: University of Antwerp Press, Centre for Evaluation of Vaccination, Epidemiology and Community Medicine, 1994.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Symposium in Immunology (7th 1997?). Symposium in Immunology VII: Vaccination. Berlin: Springer, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Centers for Disease Control (U.S.), ed. Hepatitis B prevention and pregnancy: How to protect your baby against hepatitis B. Atlanta, Ga: Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control, 1994.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Workshop on Hepatitis B Immunization in the South Pacific (1989 Suva, Fiji). Report. Manila, Philippines: The Office, 1989.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Edwards, Vivien. Battling the big B: Hepatitis B in New Zealand. Wellington [N.Z.]: Dunmore Publishing, 2006.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Honig, Robert E. A review of public and private programs that test for the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV): And issues related to vaccination programs for bloodborne diseases. [Washington, D.C.]: Dept. of Labor, 1989.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

United States. Congress. House. Committee on Government Reform. Subcommittee on Criminal Justice, Drug Policy, and Human Resources. Hepatitis B vaccine: Helping or hurting public health? : hearing before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Sixth Congress, first session, May 18, 1999. Washington: U.S. G.P.O., 2000.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Oon, Gabriel Chong Jin. A cancer vaccine that transformed Singapore and the world: The battle against Hepatitis B. Singapore: Straits Times Press Reference, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Madhavi, Y. Liberalisation and its impact on the cost-benefit aspects of vaccines: The case of Hepatitis B. Mumbai: Tata Institute of Social Sciences, 2001.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

The war against hepatitis B: A history of the International Task Force on Hepatitis B Immunization. Philadelphia: University of Pennsylvania Press, 1995.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Parker, Philip M., and James N. Parker. Hepatitis A vaccine: A medical dictionary, bibliography, and annotated research guide to Internet references. San Diego, CA: ICON Health Publications, 2004.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Mitcheson, Luke. Factors influencing compliance with hepatitis B vaccination of drugs users and development of a health intervention to improve compliance. London: UEL, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Safety, Virginia Secretary of Public. Report of the Secretary of Public Safety, the Secretary of Health and Human Resources, and the team studying hepatitis B immunization requirements for selected public health, public safety, and emergency services personnel to the Governor and the General Assembly of Virginia. Richmond: Commonwealth of Virginia, 1991.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

J, Gerety R., ed. Hepatitis B. Orlando: Academic Press, 1985.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

(Editor), Martha M. Eibl, H. H. Peter (Editor), C. Huber (Editor), and U. Uahn (Editor), eds. Symposium in Immunology VII: Vaccination. Springer-Verlag Telos, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Rajan, Elizabeth. Hepatitis A: Prevalence and the need for vaccination. 1997.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Waisbren, Burton A. The hepatitis B vaccination program in the United States-- lessons for the future. s.n, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Kourtis, Athena P., Shruti Chandramouli, Gonzague Jourdain, and Marc Bulterys. Hepatitis B Virus. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190604813.003.0004.

Повний текст джерела

Анотація:

Hepatitis B virus (HBV) is the most common cause of chronic viral hepatitis and hepatocellular carcinoma in the world. Worldwide, more than 250 million people are chronically infected with HBV, causing nearly 780,000 deaths each year, and mother-to-child transmission (MTCT) accounts for more than one-third of chronic HBV infections. Universal vaccination in neonates is the most effective strategy for eliminating infections worldwide. Maternal antiviral treatment during the antepartum/postpartum period for mothers with high HBV viral loads is effective in preventing HBV MTCT. Full immunization coverage is currently the only way to reach the goal of eradicating HBV infection. Operational research and, in some resource-limited settings, international funding may be essential to bring the vaccine where neonates and infants need it, including remote locations where home births are common. Continued improvements in the coverage and timeliness of HBV vaccination and education of clinicians about its importance are needed.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Almario, Donna A., Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, and Marie C. McCormick. Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. National Academies Press, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Almario, Donna A., Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, and Marie C. McCormick. Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. National Academies Press, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Muche, Marion, and Seema Baid-Agrawal. Hepatitis B. Edited by Vivekanand Jha. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0185_update_001.

Повний текст джерела

Анотація:

Hepatitis B virus (HBV) has been causally linked to a variety of renal diseases, the most common being glomerular diseases and systemic autoimmune disease. Membranous nephropathy (MN) is the commonest HBV-associated glomerulonephritis (HBV-GN), followed by membranoproliferative glomerulonephritis (MPGN), mesangial proliferative glomerulonephritis, immunoglobulin (Ig)-A nephropathy, and focal segmental glomerulosclerosis (FSGS). Polyarteritis nodosa is a rare manifestation. The incidence of HBV-associated renal diseases seems to be decreasing with the introduction of vaccination programmes.HBV-MN is the most frequent cause of nephrotic syndrome in children in countries with high endemicity of HBV infection. The clinical course is usually benign in children with high rates of spontaneous remission rates and low risk of progression to renal failure. The prognosis is worse in adults. Of the systemic autoimmune disorders associated with HBV infection that involve the kidneys, the strongest link has been found with polyarteritis nodosa (PAN), a lesion that causes arteritis of medium-sized renal vessels. HBV-associated PAN (HBV-PAN) usually manifests in the first year after infection, and is clinically indistinguishable from classic PAN.Diagnosis of HBV-GN or -PAN is based on the clinical picture, histological findings, evidence of viral replication in serum and/or liver and detection of HBV antigens or DNA in the tissue. Besides deposition of immune complexes, other mechanisms such as virus-induced cytopathic damage have been proposed to explain the pathogenesis.HBV-GN and HBV-PAN appear to respond to antiviral treatment. Both show remission after HBeAg seroconversion. The available studies predominantly employed first-generation agents like interferon alpha and lamivudine, which showed suppression of viral replication and clinical remission of HBV-associated renal disease. Immunosuppressive therapy appears to be inevitable for the control of severe HBV-PAN and could be helpful in addition to antiviral treatment for cases of HBV-GN not responding clinically to antiviral treatment.

Стилі APA, Harvard, Vancouver, ISO та ін.

22

US GOVERNMENT. Hepatitis B vaccine: Helping or hurting public health? : Hearing before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee ... Sixth Congress, first session, May 18, 1999. [Congressional Sales Office, Supt. of Docs., U.S. G.P.O., distributor], 2000.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

When Your Doctor is Wrong, Hepatitis B Vaccine and Autism. Xlibris Corporation, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Ellis. Hepatitis B Vaccines in Clinical Practice (Infectious Disease and Therapy). CRC, 1992.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

W, Ellis Ronald, ed. Hepatitis B vaccines in clinical practice. New York: Dekker, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Hepatitis B vaccination: Programme for sexual health clinic and general practice setting. Welwyn Garden City: SmithKline Beecham, 1994.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Winter, Rebecca J., and Margaret E. Hellard. Drug Use in Prisoners and Hepatitis. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199374847.003.0009.

Повний текст джерела

Анотація:

A corollary of the high proportion of people who inject drugs cycling through prisons worldwide is the accompanying high prevalence of viral hepatitis, particularly hepatitis C (HCV). Prisons have the potential to either escalate or interrupt the transmission of viral hepatitis: prisons that do not provide access to even basic prevention programs are high-risk environments for viral hepatitis transmission. In contrast, prisons can also reduce prevalence through testing and treatment programs. This chapter provides an overview of the global prevalence and incidence of HCV and hepatitis B (HBV) in prisons and the occurrence of known transmission vectors, including injecting drug use, tattooing and other body modification practices, and unprotected sexual intercourse. It discusses policy and practice options to reduce the risk behaviors associated with HCV and HBV transmission, prevent transmission through vaccination, and potentially expand viral hepatitis treatment in prisons using new directly acting anti-viral medication, and the prospect of treatment as prevention.

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Choi, Eun Kyung, and Young-Gyung Paik. ‘A vaccine for the nation’: South Korea’s development of a hepatitis B vaccine and national prevention strategy focused on newborns. Manchester University Press, 2017. http://dx.doi.org/10.7228/manchester/9781526110886.003.0005.

Повний текст джерела

Анотація:

For several decades South Korea has been recognised as a country in which hepatitis B is endemic, but it has also become famous for its controlled hepatitis epidemic, using a well-organised vaccination plan.The social determinants surrounding the vaccination plan have not been studied, however. In the 1980s, the hepatitis issue was a major concern in Korea, involving various actors, including medical doctors, the government, foreign scholars, and international institutions. While the domestic production of hepatitis B vaccines and the vaccination campaigns focused on newborns, combined with extensive prenatal screening have been counted as key success factors, the adoption of these specific measures was not simply based on scientific analysis. In this sense, when an anti-hepatitis plan was finally introduced in South Korea, it was not just a reaction to the prevalent hepatitis B but also a reflection of the nation’s future-oriented, developmentalist imaginaries.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

P, Coursaget, Tong M. J, Institut national de la santé et de la recherche médicale (France), and Université de Tours, eds. Progress in hepatitis B immunization: Proceedings of a symposium = La vaccination contre l'hépatite B. Paris: Les editions INSERM ; London ; Paris : John Libbey Eurotext, 1990.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Burchell, Ann, and Eduardo Franco1. The impact of immunization on cancer control: the example of HPV vaccination. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199550173.003.0006.

Повний текст джерела

Анотація:

Chapter 6 reviews briefly the role of infections as causal agents in cancer, describes anti-hepatitis B virus (HBV) immunization as the first cancer vaccine paradigm, and finally focuses on the latest paradigm of prophylactic vaccination against human papillomavirus (HPV) infection as the new front in cancer prevention.

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Bulterys, Marc, Julia Brotherton, and Ding-Shinn Chen. Prevention of Infection-Related Cancers. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0066.

Повний текст джерела

Анотація:

This chapter discusses primary prevention measures that disrupt transmission of oncogenic infections. It begins by discussing vaccination against hepatitis B virus (HBV) and human papillomavirus (HPV), two major causes of cancer for which safe and effective vaccines are currently available. It briefly discusses the importance of treatment and prophylaxis against human immunodeficiency virus type 1 (HIV-1), which potentiates the virulence of other viral infections as well as directly increasing the incidence of non-Hodgkin lymphoma. It does not discuss the treatment of HBV or hepatitis C virus (HCV) infection, since these are considered in Chapters 25 and 33. Also beyond the scope of this chapter are the randomized clinical trials currently underway to assess the efficacy and feasibility of eradication of Helicobacter pylori (Chapters 24, 31), vaccination against Epstein-Barr virus (EBV) (Chapters 24, 26, 39), or the prevention of schistosomiasis and liver flukes (Chapters 24, 33, and 52).

Стилі APA, Harvard, Vancouver, ISO та ін.

32

(Editor), Kathleen Stratton, Donna Almario (Editor), and Marie C. McCormick (Editor), eds. Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. National Academies Press, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Immunization safety review: Hepatitis B vaccine and demyelinating neurological disorders. Washington, D.C: National Academies Press, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Wilson, John W., and Lynn L. Estes. Infectious Syndromes in Adults. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190696924.003.0005.

Повний текст джерела

Анотація:

This section contains tables and text covering an exhaustive group of infectious syndromes including respiratory tract infections, infective endocarditis, intravascular catheter-related infections, central nervous system infections, urinary tract infections, soft-tissue infections, osteomyelitis, gastrointestinal infections, tick-borne infections, tuberculosis, sexually transmitted diseases, HIV, hepatitis, and fungal and zoonotic infections. Vaccination schedules, travel medicine, and bioterrorism are also reviewed.

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Almario, Donna, Institute of Medicine, Immunization Safety Review Committee, Kathleen Stratton, and Marie C. McCormick. Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. National Academies Press, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

(Editor), Kathleen Stratton, Donna A. Almario (Editor), Theresa M. Wizemann (Editor), and Marie C. McCormick (Editor), eds. Immunization Safety Review: Vaccinations and Sudden Unexpected Death in Infancy. National Academies Press, 2003.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Franceschi, Silvia, Hashem B. El-Serag, David Forman, Robert Newton, and Martyn Plummer. Infectious Agents. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0024.

Повний текст джерела

Анотація:

Eleven infectious agents (seven viruses, three parasites, and one bacterium) have been classified by the International Agency for Research on Cancer as carcinogenic to humans for one or more cancer sites: hepatitis B virus; hepatitis C virus; thirteen types of human papillomavirus (HPV); human immunodeficiency virus type 1 (HIV-1); human T-cell leukemia virus type 1; Epstein-Barr virus; Kaposi sarcoma herpesvirus; Helicobacter pylori; Opisthorchis viverrini; Clonorchis sinensis; and Schistosoma haematobium. Other infectious agents, such as Merkel cell polyomavirus, Plasmodium falciparum, and cutaneous HPVs, have been classified as “probably carcinogenic” or “possibly carcinogenic.” Accurate biomarkers of chronic infection have been essential for estimating risk and ascribing a causal role to infectious agents in cancer. Of the 14 million cases of cancer estimated to have occurred worldwide in 2012, 2.2 million were caused by infectious agents. Vaccination and screen-and-treat programs have the potential for greatly reducing the burden of cancer caused by infections.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Nuevas generaciones sin la infección por el VIH, la sífilis, la hepatitis B y la enfermedad de Chagas en las Américas 2018. ETMI Plus. Organización Panamericana de la Salud, 2019. http://dx.doi.org/10.37774/9789275120675.

Повний текст джерела

Анотація:

En el presente documento se comunica el progreso logrado en la Región hacia la eliminación de la transmisión maternoinfantil del VIH y la sífilis entre los años 2010 y 2017. Se trata también del primer informe regional sobre la eliminación de la transmisión maternoinfantil y durante la primera infancia de la hepatitis B y la enfermedad de Chagas congénita. Los resultados principales son los siguientes: El acceso de las embarazadas a la atención prenatal y del parto es alto en la Región de las Américas. El tamizaje de la infección por el VIH y la sífilis en las embarazadas sigue siendo alto, pero se han logrado pocos avances para salvar las brechas; por otra parte, el tamizaje de la enfermedad de Chagas en las embarazadas es muy variable, dado que oscila entre 7% y 55% en los pocos países que presentan informes al respecto. El tratamiento de la infección por el VIH y la sífilis en las embarazadas seropositivas sigue en aumento. La vacunación contra la hepatitis B se ha estabilizado en 87% de los menores de 1 año que completan su tercera dosis, aunque continúa en aumento la adopción de políticas de administración de una dosis al nacer de la vacuna contra el virus de la hepatitis B a todos los recién nacidos. Durante mucho tiempo se ha observado una disminución continua de la transmisión maternoinfantil del VIH, pero comienza a estabilizarse. Los casos de sífilis congénita están en aumento. Se considera que la transmisión maternoinfantil causa más de 20% de los casos nuevos de enfermedad de Chagas. This document reports the progress made in the Americas towards the EMTCT of HIV and syphilis between 2010 and 2017. It is the first Regional report regarding elimination of mother-to-child and early childhood transmission of hepatitis B and congenital Chagas disease. The main findings are as follows: Access to prenatal and delivery care for pregnant women is high in the Americas. Screening of pregnant women for HIV and syphilis remains high but little progress has been made in closing the gaps; meanwhile, screening of pregnant women for Chagas disease varies widely, ranging from 7% to 55% among the few reporting countries. HIV and syphilis treatment of seropositive pregnant women continues to increase. Vaccination for hepatitis B has stabilized at 87% of children under one year old who completed their third dose, and policies for universal timely hepatitis B vaccine birth dose are increasingly being adopted. MTCT of HIV experienced longstanding reductions but has begun to stabilize. Congenital syphilis cases are on the rise. Mother-to-child transmission is estimated to cause over 20% of new cases of Chagas disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Thun, Michael J., Christopher P. Wild, and Graham Colditz. Framework for Understanding Cancer Prevention. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0061.

Повний текст джерела

Анотація:

The worldwide increase in the number of people affected by cancer and the costs of cancer care has increased the urgency of efforts to translate knowledge about the causes of cancer into effective preventive interventions. A wide range of interventions has proven to be effective for cancer prevention, either by reducing exposure to known causes of human cancer or by disrupting the multistage progression of tumors. Examples of progress include the up to 40% decrease in the age-standardized lung cancer incidence rate among men in high- and middle-income countries due to tobacco control; the 30% decrease in colorectal cancer incidence in the United States from widespread screening and the removal of precursor adenomatous tumors; the decreased prevalence of chronic hepatitis B virus (HBV) infection in East Asia due to neonatal vaccination; and protection against excessive sun exposure and decreased incidence of melanoma and keratinocytic carcinomas in Australia.

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Putman, Shannon B. Cervicitis and Vulvovaginitis. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199976805.003.0038.

Повний текст джерела

Анотація:

Cervicitis is inflammation and irritation of uterine cervix often caused by sexually transmitted infection (STI); it can lead to pelvic inflammatory disease, endometritis, and pregnancy complications. Vulvovaginitis (inflammation of vagina and/or vulva with itching, erythema, and mucopurulent discharge) may or may not be related to STI. Sexually active women 25 years or younger with STIs should be offered empiric treatment for gonorrhea and chlamydia in addition to counseling regarding safe sex and testing for syphilis, HIV, and viral hepatitis at the time of presentation and prior to nucleic acid amplification testing results. Sexual partners of women testing positive for gonorrhea, chlamydia, or trichomoniasis should be informed and treated to prevent reinfection, with patients and their partners abstaining from intercourse until treatment is complete and symptoms resolve. High-risk patients with STI should be retested at 6 months given recurrent infection rates. Prophylaxis, vaccination, high degree of suspicion, and early intervention can help improve morbidity and mortality.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Newman, Chris, and Andrew Byrne. Musteloid diseases: implications for conservation and species management. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780198759805.003.0009.

Повний текст джерела

Анотація:

The role of disease in population regulation is often overlooked in ecology and conservation. Due to their diversity, the musteloids host a wide range of pathogens. These include diseases of commercial importance, such Aleutian mink disease virus which impacts mink ranching, or bovine tuberculosis leading to interventions to manage European badgers. Skunks and raccoons are major rabies hosts in North America, and because these small carnivores insinuate themselves into close proximity with people, they can pose substantial zoonotic risks. Musteloids also share diseases between species, such as mustelid herpes virus, canine distemper and infectious hepatitis viruses, along with a range of nematodes and protozoans; presenting a contagion risk when vulnerable musteloids are being conserved or reintroduced. Managing host density, vaccination and host isolation are thus the best tools for managing disease, where we advocate the UN-led ‘One Health approach, aimed at reducing risks of infectious diseases at the Animal-Human-Ecosystem interface

Стилі APA, Harvard, Vancouver, ISO та ін.

42

(Editor), Kathleen Stratton, Donna A. Alamario (Editor), Theresa Wizemann (Editor), and Marie C. McCormick (Editor), eds. Immunization Safety Review: Influenza Vaccines and Neurological Complications. National Academies Press, 2004.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

(Editor), Kathleen Stratton, Donna A. Almario (Editor), and Marie C. McCormick (Editor), eds. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. National Academies Press, 2003.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

R, Stratton Kathleen, Alamario Donna A, McCormick Marie C, and Institute of Medicine (U.S.). Immunization Safety Review Committee., eds. Immunization safety review: SV40 contamination of polio vaccine and cancer. Washington, D.C: National Academies Press, 2003.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Oldstone, Michael B. A. Viruses, Plagues, and History. Oxford University Press, 2020. http://dx.doi.org/10.1093/oso/9780190056780.001.0001.

Повний текст джерела

Анотація:

“Viruses, Plagues, & History” focuses on the effects of viral diseases on human history. Written by an eminent internationally respected virologist, it couples the fabric of history with major concepts developed in virology, immunology, vaccination, and accounts by people who first had, saw and acted at the times these events occurred. Much of the preventive and therapeutic progress (vaccines, antiviral drugs) has been made in the last 60 years. Many of those who played commanding roles in the fight to understand, control and eradicate viruses and viral diseases are (were) personally known to the author and several episodes described in this book reflect their input. The book records the amazing accomplishments that led to the control of lethal and disabling viral diseases caused by Smallpox, Yellow Fever, Measles, Polio, Hepatitis A, B and C, and HIV. These six success stories are contrasted with viral infections currently out of control—COVID-19, Ebola virus, Lassa Fever virus, Hantavirus, West Nile virus, and Zika. Influenza, under reasonable containment at present, but with the potential to revert to a world-wide pandemic similar to 1918–1919 where over 50 million people were killed. The new platforms to develop inhibitory and prophylactic vaccines to limit these and other viral diseases is contrasted to the anti-vaccine movement and the false prophets of autism.

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Karen, Bellenir, and Dresser Peter D, eds. Contagious and non-contagious infectious diseases sourcebook: Basic information about contagious diseases like measles, polio, hepatitis B, and infectious mononucleosis, non-contagious infectious diseases like tetanus and toxic shock syndrome, and diseases occurring as secondary infections such as shingles and Reye syndrome along with vaccination, prevention, and treatment information and a section describing emerging infectious disease threats. Detroit, MI: Omnigraphics, 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Jadoul, Michel, Laura Labriola, and Eric Goffin. Viral infections in patients on dialysis. Edited by Jonathan Himmelfarb. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0271.

Повний текст джерела

Анотація:

From the early days of hemodialysis, viral hepatitis has been recognized as common in dialyzed patients.The prevalence and incidence of HBV infection have decreased markedly over the last decades in HD units. Still, the infectivity of HBV is very high. Vaccinating HD patients, preferably prior to starting dialysis, together with the strict application of hygienic precautions and adequate screening of blood donors remains required, together with the segregation of infective (HBV+) patients in a separate dialysis ward. The level of aminotransferases is markedly lower in HD patients than in the general population: any level above the normal range should thus trigger the suspicion of acute hepatitis (viral or not). The treatment of HBV infection in HD patients is rarely required, unless they are scheduled for a kidney transplant.Screening for HCV infection usually relies on a modern ELISA test. The prevalence and incidence of HCV infection in HD patients has also decreased substantially but remains higher than in the general population. The risk of post-transfusional HCV is currently extremely low, at least in western countries. The actual application of basic hygienic precautions is crucial if nosocomial transmission of HCV is to be prevented. These include optimal hand hygiene practices (hydroalcoholic solution use before contact with patient and after gloves withdrawal), the systematic wearing of gloves, to be changed between patients/stations, an adequate separation of the clean and contaminated items and circuits within the HD unit, and regular cleaning/disinfection of potentially contaminated surfaces. The necessity and usefulness to isolate HCV positive patients in a separate dialysis ward has not been demonstrated and is not recommended by current KDIGO guidelines. The field of the treatment of HCV infection is changing rapidly with many orally active drugs, some of which can be used even in dialysis patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Hepatitis A Vaccination"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями